CA1333152C - Vaccine containing tumor antigens and adjuvants - Google Patents

Vaccine containing tumor antigens and adjuvants

Info

Publication number
CA1333152C
CA1333152C CA000578719A CA578719A CA1333152C CA 1333152 C CA1333152 C CA 1333152C CA 000578719 A CA000578719 A CA 000578719A CA 578719 A CA578719 A CA 578719A CA 1333152 C CA1333152 C CA 1333152C
Authority
CA
Canada
Prior art keywords
tumor
vaccine
mpl
tumors
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000578719A
Other languages
English (en)
French (fr)
Inventor
John Leonard Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Application granted granted Critical
Publication of CA1333152C publication Critical patent/CA1333152C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA000578719A 1987-09-30 1988-09-28 Vaccine containing tumor antigens and adjuvants Expired - Fee Related CA1333152C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/102,909 US4877611A (en) 1986-04-15 1987-09-30 Vaccine containing tumor antigens and adjuvants
US102,909 1987-09-30

Publications (1)

Publication Number Publication Date
CA1333152C true CA1333152C (en) 1994-11-22

Family

ID=22292343

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000578719A Expired - Fee Related CA1333152C (en) 1987-09-30 1988-09-28 Vaccine containing tumor antigens and adjuvants

Country Status (10)

Country Link
US (1) US4877611A (enExample)
JP (1) JPH01163130A (enExample)
BE (1) BE1001634A4 (enExample)
CA (1) CA1333152C (enExample)
CH (1) CH678492A5 (enExample)
DE (1) DE3833319A1 (enExample)
FR (1) FR2620941B1 (enExample)
GB (1) GB2210557B (enExample)
IT (1) IT1226861B (enExample)
NL (1) NL8802393A (enExample)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
ATE133994T1 (de) * 1987-12-09 1996-02-15 Gen Hospital Corp An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US6093406A (en) * 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
ES2019728A6 (es) * 1988-09-23 1991-07-01 Univ Southern California Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.
US4963364A (en) * 1989-04-10 1990-10-16 Fox Sidney W Microencapsulated antitumor agent
WO1990014357A1 (en) * 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
US6177083B1 (en) * 1990-07-26 2001-01-23 Evax Technologies Gmbh Process for the production of vaccines and their use
CA2049533A1 (en) * 1990-08-20 1992-02-21 Gen-Ichiro Soma Lps-containing analgesics and veterinary analgesics
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
EP0533517A1 (en) * 1991-08-20 1993-03-24 Chiba Flour Milling Co. Ltd. LPS-containing anti-withdrawal agents
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
CZ282235B6 (cs) * 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Očkovací prostředek, jeho použití k výrobě vakcíny, způsob léčby patogenních infekcí tímto prostředkem a způsob jeho výroby
AU6409894A (en) * 1993-03-16 1994-10-11 Samuel Bogoch Recognin vaccines
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
DE69434475T2 (de) * 1993-08-11 2006-05-18 Jenner Technologies, Tiburon Impfstoff gegen prostatakrebs
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
USD365131S (en) 1994-05-25 1995-12-12 Royal Grip, Inc. Golf club grip
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6689370B1 (en) 1995-04-20 2004-02-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US6303584B1 (en) 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
PT1003525E (pt) 1997-08-05 2003-03-31 Bioniche Life Sciences Inc Composicao e metodo para a regulacao da proliferacao e da morte celular
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
EP1097715A4 (en) * 1998-07-16 2004-12-29 Hayashi Akira PREPARATIONS FOR ANTICANCER IMMUNOTHERAPY COMPRISING A BACTERIAL SOMATIC COMPONENT AS AN ACTIVE INGREDIENT
BR9912671A (pt) 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
KR20070108263A (ko) 1998-12-08 2007-11-08 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를포함하는 약제학적 조성물 및 진단 키트
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
EA005140B1 (ru) 1999-04-02 2004-12-30 Корикса Корпорейшн Соединения и способы для лечения и диагностики рака легкого
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
ES2288883T3 (es) * 1999-12-13 2008-02-01 Bioniche Life Sciences Inc. Oligonucleotidos sinteticos utiles terapeuticamente.
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
CA2400842C (en) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
EP2000144A1 (en) 2000-05-19 2008-12-10 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
EP2133100B1 (en) * 2000-06-20 2011-10-05 Corixa Corporation MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
DE60134158D1 (de) 2000-06-28 2008-07-03 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20030108565A1 (en) 2001-07-10 2003-06-12 Johnson Mark E. Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
IL160809A0 (en) 2001-09-20 2004-08-31 Glaxo Group Ltd HIV-gag CODON-OPTIMISED DNA VACCINES
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
WO2003053220A2 (en) 2001-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20040033213A1 (en) * 2002-02-28 2004-02-19 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP1523582B1 (en) 2002-07-18 2008-11-12 University of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
US7563771B2 (en) * 2002-11-13 2009-07-21 Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
KR20110120989A (ko) 2003-01-06 2011-11-04 코릭사 코포레이션 특정의 아미노알킬 글루코사미나이드 포스페이트 화합물 및 그들의 용도
AU2005206388A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
ATE491467T1 (de) 2004-05-28 2011-01-15 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
US8846051B2 (en) 2004-10-08 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by deoptimization of synonymous codons
WO2006065549A2 (en) 2004-12-03 2006-06-22 Medical University Of Ohio Attenuated vaccine useful for immunizations against coccidioides spp. infections
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
EP1868641A2 (en) 2005-03-31 2007-12-26 GlaxoSmithKline Biologicals SA Vaccines against chlamydial infection
KR20120089475A (ko) 2005-04-29 2012-08-10 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
US8017754B2 (en) * 2005-07-22 2011-09-13 Research Development Foundation Attenuated virus strains and uses thereof
EP1937301B1 (en) 2005-10-18 2015-04-22 Novavax, Inc. Functional influenza virus like particles (vlps)
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
PT2068918E (pt) 2006-09-26 2012-08-06 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5578390B2 (ja) * 2007-03-05 2014-08-27 株式会社 Ｍｂｒ 細菌細胞壁骨格成分の製造方法
MX2009010800A (es) 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2170384B1 (en) 2007-07-02 2016-04-13 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
PT2540312E (pt) 2007-07-19 2015-08-31 Novavax Inc Vlps quiméricas de gripe aviária
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP4219566A3 (en) * 2007-12-24 2023-09-06 ID Biomedical Corporation of Quebec Recombinant rsv antigens
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2300041B1 (en) 2008-04-16 2016-01-27 The Johns Hopkins University Method for determining risk of recurrence of prostate cancer
CN102131830A (zh) * 2008-07-18 2011-07-20 魁北克益得生物医学公司 嵌合呼吸道合胞病毒多肽抗原
US8697854B2 (en) 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
CN102317308A (zh) 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
MX345700B (es) 2008-12-09 2017-02-10 Novavax Inc Proteinas f del vrs modificadas y metodos de uso de las mismas.
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EA023054B1 (ru) 2009-06-24 2016-04-29 Глэксосмитклайн Байолоджикалз С.А. Рекомбинантные антигены pcb
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
CN107029229B (zh) 2009-07-06 2022-08-26 变异生物技术公司 制备囊泡的方法和由其产生的制剂
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
DK3178490T3 (da) 2009-07-15 2022-06-20 Glaxosmithkline Biologicals Sa RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
KR101125764B1 (ko) 2010-01-27 2012-03-27 백태현 항산균 세포벽골격을 이용한 백신매개체 및 그에 의한 백신의 제조 방법
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトｃｄ２７に結合する抗体およびその使用
AU2011271495B2 (en) * 2010-07-02 2014-05-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine against Ehrlichia canis
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
MA34802B1 (fr) 2010-10-15 2014-01-02 Glaxosmithkline Biolog Sa Nouvel antigène
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
DK2635257T3 (en) 2010-11-05 2017-09-04 Novavax Inc Rabies virus-like glycoprotein particles (VLP)
WO2012064659A1 (en) 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
EA027504B1 (ru) 2010-12-14 2017-08-31 Глаксосмитклайн Байолоджикалс С.А. Композиция микобактериальных антигенов
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
WO2013111012A2 (en) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
EP2827891A1 (en) 2012-03-18 2015-01-28 GlaxoSmithKline Biologicals S.A. Method of vaccination against human papillomavirus
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
US20150182612A1 (en) 2012-08-03 2015-07-02 Infectious Disease Research Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
HRP20230359T1 (hr) 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak
CN105473604B (zh) 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
EP2968521A2 (en) 2013-03-15 2016-01-20 GlaxoSmithKline Biologicals S.A. Vaccine
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
MX2016001901A (es) 2013-08-12 2016-10-13 Tokai Pharmaceuticals Inc Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
US10751410B2 (en) 2013-09-19 2020-08-25 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
EP3146081B1 (en) 2014-05-19 2020-10-28 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
BR112016028816A8 (pt) 2014-06-13 2021-07-20 Glaxosmithkline Biologicals Sa combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
SI3160500T1 (sl) 2014-06-25 2019-11-29 Glaxosmithkline Biologicals Sa Imunogeni sestavek proti Clostridium difficile
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
WO2016033114A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
JP6738348B2 (ja) 2014-12-19 2020-08-12 リジェネサンス ベスローテン フェンノートシャップ ヒトｃ６に結合する抗体およびその使用
EP3242940B1 (en) 2015-01-09 2023-03-29 Etubics Corporation Methods and compositions for combination immunotherapy
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EP3302544A4 (en) 2015-05-26 2019-01-09 Ohio State Innovation Foundation NANOPARTICLE-BASED VACCINE STRATEGY AGAINST SWINE INFLUENZA VIRUS
US20170226171A1 (en) * 2016-02-09 2017-08-10 Vaccinogen, Inc. Adenocarcinoma antigenic determinants and methods
JP2019511483A (ja) 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
JP2019521095A (ja) 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
US11801290B2 (en) 2016-09-16 2023-10-31 Access To Advanced Health Institute Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals S.A. métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
MX2019006349A (es) 2016-12-16 2019-08-22 Inst Res Biomedicine Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
US20210046177A1 (en) 2018-01-26 2021-02-18 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
US20190275135A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against intra-abdominal infections
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
MX2021001129A (es) 2018-07-31 2021-07-02 Glaxosmithkline Biologicals Sa Metodo de purificacion de antigenos.
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020163875A1 (en) * 2019-02-08 2020-08-13 University Of Florida Research Foundation, Inc. A monophosphoryl lipid-a liposome based cancer vaccine
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
US12419949B2 (en) 2019-07-24 2025-09-23 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
JP2022547298A (ja) 2019-09-09 2022-11-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫療法組成物
CN115151559A (zh) 2019-10-02 2022-10-04 扬森疫苗与预防公司 葡萄球菌肽和使用方法
EP4077356A1 (en) 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA S. aureus antigens and compositions thereof
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021178637A1 (en) 2020-03-05 2021-09-10 Iowa State University Research Foundation, Inc. IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
WO2021214766A1 (en) 2020-04-21 2021-10-28 Yeda Research And Development Co. Ltd. Methods of diagnosing viral infections and vaccines thereto
US20230277657A1 (en) 2020-05-05 2023-09-07 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
US20230236205A1 (en) 2020-06-01 2023-07-27 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
EP4255919A2 (en) 2020-12-02 2023-10-11 GlaxoSmithKline Biologicals S.A. Donor strand complemented fimh
MX2023006769A (es) 2020-12-09 2023-08-18 Glaxosmithkline Biologicals Sa Modificacion de saponinas.
US20240102069A1 (en) 2020-12-24 2024-03-28 Plant Bioscience Limited Methods and compositions
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途
US20240131140A1 (en) 2021-02-11 2024-04-25 Glaxosmithkline Biologicals Sa Hpv vaccine manufacture
US12290563B2 (en) 2021-04-01 2025-05-06 Janssen Pharmaceuticals, Inc. Production of E. coli 018 bioconjugates
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023180677A1 (en) 2022-03-25 2023-09-28 Plant Bioscience Limited Biosynthesis
CN119403935A (zh) 2022-06-15 2025-02-07 葛兰素史克生物有限公司 皂苷的酶促修饰
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4676956A2 (en) 2023-03-03 2026-01-14 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
CN116712565A (zh) * 2023-06-12 2023-09-08 南京鼓楼医院 一种口服胃癌疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (enExample) * 1971-11-19 1975-02-07 Anvar
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505903A (en) * 1982-06-30 1985-03-19 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use

Also Published As

Publication number Publication date
IT1226861B (it) 1991-02-19
GB2210557B (en) 1991-11-13
JPH01163130A (ja) 1989-06-27
IT8822145A0 (it) 1988-09-30
DE3833319A1 (de) 1989-04-13
GB8822749D0 (en) 1988-11-02
CH678492A5 (enExample) 1991-09-30
FR2620941B1 (fr) 1990-08-10
BE1001634A4 (fr) 1990-01-02
NL8802393A (nl) 1989-04-17
US4877611A (en) 1989-10-31
FR2620941A1 (fr) 1989-03-31
JPH0575731B2 (enExample) 1993-10-21
DE3833319C2 (enExample) 1992-06-11
GB2210557A (en) 1989-06-14

Similar Documents

Publication Publication Date Title
CA1333152C (en) Vaccine containing tumor antigens and adjuvants
CA1217136A (en) Refined detoxified endotoxin product
RU2325184C2 (ru) Улучшенные везикулы наружной мембраны бактерий
JPS6345225A (ja) 精製無毒化エンドトキシンを含有する抗腫瘍性組成物
EP0375808A1 (en) Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and a kit of parts
US4505900A (en) Refined detoxified endotoxin product
Ribi et al. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins
AU691797B2 (en) Immunotherapeutic composition
US8277778B2 (en) Vaccine adjuvants
WO2003049751A1 (en) The process of manufacturing a pharmaceutical composition useful for management of cancer
US7972609B2 (en) Method of treating cancer
Butler et al. Combined immunostimulation in the prevention of tumor take in mice using endotoxins, their derivatives, and other immune adjuvants
CN118201633A (zh) 气肿疽梭菌疫苗和其制备方法
CA1202903A (en) Stable composition and preparation thereof
GB2122896A (en) Anti-tumour microorganism obtained products
Butler Enhancement of nonspecific resistance to tumor by endotoxin
Mathé Developmental Pharmacology
Martin UN: VERSITY Of UTAH LIBRARIES

Legal Events

Date Code Title Description
MKLA Lapsed